Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GV 150526A

Known as: GV-150526A, GV150526, GV150526A 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
PurposeThe aim of this study was to investigate and quantify drug movement to the brain via the neuro-olfactory system after… Expand
  • table I
  • figure 1
  • table II
  • table III
  • table IV
Is this relevant?
2006
2006
Background and Purpose: Gavestinel, GV150526, is a selective antagonist at the glycine site of the N-methyl-D-aspartate receptor… Expand
  • table 4
  • table 1
  • table 2
  • table 3
Is this relevant?
2002
2002
SUMMARY During cerebral ischaemia, glutamate is released in supraphysiological amounts and is toxic to brain tissue. This… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
CONTEXT Elucidation of the ischemic cascade has helped stimulate development of neuroprotective drugs aimed at limiting brain… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2001
2001
GV150526 is a novel glycine antagonist at the NMDA receptor complex. It is a potent neuroprotective agent in animal models of… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
1999
1999
BACKGROUND AND PURPOSE GV150526 is a novel glycine site antagonist at the N-methyl-D-aspartate receptor complex. It is a potent… Expand
Is this relevant?
1999
1999
The utility of interspecies scaling in early drug development has been extensively debated. The authors discuss the dose… Expand
Is this relevant?
1999
1999
The neuroprotective activity of the novel glycine receptor antagonist (E)-3[(phenylcarbamoil)ethenil]-4,6-dichloroindole-2-c… Expand
Is this relevant?
1997
1997
The N-methyl-D-aspartate (NMDA) receptor is a ligand-gated ion channel which is widely distributed in the central nervous system… Expand
Is this relevant?
1997
1997
The neuroprotective activity of the novel, selective glycine antagonist GV150526 was assessed in the middle artery occlusion… Expand
Is this relevant?